Mechanical circulatory support in patients with severe aortic stenosis and  left ventricular dysfunction undergoing percutaneous coronary intervention by Alkhouli, Mohamad et al.
Clinical and Translational Science Institute Centers 
4-1-2017 
Mechanical circulatory support in patients with severe aortic 
stenosis and left ventricular dysfunction undergoing 
percutaneous coronary intervention 
Mohamad Alkhouli 
West Virginia University 
Ahmed Al Mustafa 
West Virginia University 
Zakeih Chaker 
West Virginia University 
Fahad Alqahtani 
West Virginia University 
Sami Aljohani 
West Virginia University 
See next page for additional authors Follow this and additional works at: https://researchrepository.wvu.edu/ctsi 
 Part of the Medicine and Health Sciences Commons 
Digital Commons Citation 
Alkhouli, Mohamad; Al Mustafa, Ahmed; Chaker, Zakeih; Alqahtani, Fahad; Aljohani, Sami; and Holmes, 
David R., "Mechanical circulatory support in patients with severe aortic stenosis and left ventricular 
dysfunction undergoing percutaneous coronary intervention" (2017). Clinical and Translational Science 
Institute. 598. 
https://researchrepository.wvu.edu/ctsi/598 
This Article is brought to you for free and open access by the Centers at The Research Repository @ WVU. It has 
been accepted for inclusion in Clinical and Translational Science Institute by an authorized administrator of The 
Research Repository @ WVU. For more information, please contact ian.harmon@mail.wvu.edu. 
Authors 
Mohamad Alkhouli, Ahmed Al Mustafa, Zakeih Chaker, Fahad Alqahtani, Sami Aljohani, and David R. 
Holmes 
This article is available at The Research Repository @ WVU: https://researchrepository.wvu.edu/ctsi/598 
Mechanical circulatory support in patients with severe aortic 
stenosis and left ventricular dysfunction undergoing 
percutaneous coronary intervention
Mohamad Alkhouli, MD1,2, Ahmed Al Mustafa, MD, Zakeih Chaker, MD, Fahad Alqahtani, 
MD1, Sami Aljohani, MD1, and David R. Holmes, MD2
1WVU Heart and Vascular Institute, West Virginia University School of Medicine, Morgantown, 
West Virginia
2Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota
Abstract
Management of obstructive coronary artery disease in patients with aortic stenosis and severe left 
ventricular dysfunction is challenging. Mechanical circulatory support at the time of percutaneous 
coronary interventions may be necessary in these extreme-risk patients. We present a case in 
which the TandemHeart was used to support a patient with severe aortic stenosis, severe protected 
left main and circumflex disease, and severe cardiomyopathy and review the literature on this 
subject.
Keywords
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1. INTRODUCTION
Since the introduction of transcatheter aortic valve replacement (TAVR), the number of 
patients with severe aortic stenosis (AS) undergoing transcatheter or surgical aortic valve 
replacement has increased substantially.1,2 Significant coronary artery disease (CAD) is 
present in 40% to 75% of patients with severe AS undergoing TAVR.1,3 Currently, there are 
no guidelines with regards to percutaneous coronary intervention (PCI) in these patients.3–5 
Between 25% and 32% of patients with severe AS undergoing TAVR have reduced left 
ventricular (LV) ejection fraction (LVEF; <50%), of whom one third have severe LV 
dysfunction (LVEF <30%).1,3,5,6 Patients with severe AS with LVEF <30% have worse post-
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PCI outcomes.3 Mechanical circulatory support (MCS) devices have been used for 
hemodynamic rescue, to facilitate valvuloplasty, and to support high-risk TAVR in patients 
with severe AS.7–9 Whether utilizing an LV support device improves PCI outcomes in this 
group of patients is not known. In this review, we describe a patient with severe AS and 
severe LV dysfunction who was referred for a protected left main (LM) coronary 
intervention. We discuss the challenges associated with the management of these patients 
with special emphasis on the utility of MCS and review the literature on this subject.
2. PATIENT PROFILE
The Institutional Review Board approved the current study and informed consent has been 
waived. A 72-year-old male was referred due to worsening dyspnea of 6-month duration. He 
had CAD with a history of coronary artery bypass grafting, ischemic cardiomyopathy, 
implantable cardioverter defibrillator, sleep apnea, chronic renal insufficiency (glomerular 
[glow-MAIR-you-lure] filtration rate 48 mL/min), severe carotid artery disease, morbid 
obesity, and type-II diabetes mellitus. He has been on appropriate guideline-recommended 
heart failure medications but was only able to tolerate low doses due to borderline blood 
pressure (Lisinopril 5 mg daily, Spironolactone 25 mg daily). His electrocardiogram showed 
regular sinus rhythm and right bundle branch block. His transthoracic echocardiogram 
revealed severe LV systolic dysfunction (LVEF = 29%), an aortic valve area of 0.76 cm2, 
and a mean transaortic gradient of 18 mmHg with moderate mitral and tricuspid 
regurgitation and an estimated right ventricular systolic pressure of 57 mmHg. With 
doubtamine infusion (20 mcg/kg/min), the valve area increased to 0.9 cm2 and mean 
gradient increased to 34 mmHg. Stroke volume increased by 49%, suggesting an excellent 
contractile reserve. His coronary angiogram showed severe LM coronary stenosis extending 
to the left circumflex, mild disease of the left anterior descending (LAD) coronary artery and 
60% stenosis in the right coronary artery. It also showed a patent left internal mammary to 
LAD/diagonal but an occluded saphenous vein graft to the first obtuse marginal coronary 
artery (Figure 1, Video S1). Computed tomography angiography of the abdomen and pelvis 
revealed mild tortuosity of the iliac arteries, scattered aortic and iliofemoral calcification, 
and a minimum luminal diameter >6 mm in the iliac and common femoral arteries (CFA).
After a multidisciplinary team evaluation, he was deemed not to be a suitable candidate for 
concomitant aortic replacement and redo bypass grafting (Society of Thoracic Surgeons 
score 8.6%). It was therefore decided to proceed with PCI in anticipation of a subsequent 
TAVR. LV support with TandemHeart (Cardiac Assist, Pittsburgh, PA) was planned. A 6-
French sheath was inserted in the left-CFA, two Proglide suture-mediated closure devices 
(Abbott Vascular, Redwood City, CA) were placed, and the sheath was upsized to a 12-
French Cook sheath (Cook, Bloomington, IN). Then, a 7-French 45-cm brite-tip sheath 
(Cordis, Hialeah, FL) was inserted in the right-CFA, to provide access for the PCI. The right 
femoral vein was accessed and two Proglide devices were deployed. Transseptal puncture 
was performed with a Mullins sheath and a Brockenbrough needle (Medtronic, Minneapolis, 
MN) under biplane-fluoroscopy guidance. Over an Inoue wire (Toray, Tokyo, Japan), the 
septum was dilated with sequential TandemHeart dilators, and the 21-French LA cannula 
was placed in the mid LA. The left CFA sheath was exchanged with the 17-French arterial 
cannula over an Amplatz 0.035” super-stiff wire (Boston Scientific, Marlborough, MA). The 
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system was connected to the TandemHeart centrifugal pump, and the pump was turned on, 
providing cardiac output support of 4–4.5 L/min.
Immediately after engaging the LM with a 7-French JL-4 guiding catheter (Boston 
Scientific), the LM became completely occluded (Figure 2A, Video S2). The patient 
remained stable but had very-low pulse pressures suggesting complete dependence on 
Tandem-Heart support (Figure 3). The guide was exchanged with a 7-French XB3.5 guide 
(Boston Scientific) and LM was crossed with a 0.014” Whisper wire (Abbott Vascular). 
Balloon dilatation of the ostial LM was performed with a 2.0 × 12-mm Emerge non-
compliant balloon (Boston Scientific) restoring Thrombolysis in Myocardial Infarction-III 
flow. A Pilot-50 wire (Abbott Vascular) was then used to cross the LM into the Circumflex. 
The LM-Circumflex lesion was then aggressively dilated with 3.5 × 15-mm and 4 × 20-mm 
Emerge non-compliant balloons (Figure 2B and C). A 4 × 20-mm Promus drug-eluting stent 
(Boston Scientific) was deployed and post-dilated with a 4.5 × 15-mm Emerge noncompliant 
balloon (Figure 2D, Video S3). Hemostasis was achieved with the previously placed per 
close suture-mediated closure devices. The patient was discharged home the following day 
on dual antiplatelet therapy (Aspirin 81 mg and Plavix 75 mg daily). The plan was to 
perform TAVR in 4–6 weeks. However, the patient had a dramatic improvement in his 
symptoms and opted to continue medical management only. A transthoracic echocardiogram 
done 3 months later showed a slightly improved LVEF 35%, and a small residual atrial 
septal defect. The defect was not closed because it was tolerated well and because many of 
these defects close spontaneously within a few months.10
3. DISCUSSION
This case illustrates the challenges of managing CAD in patients with severe AS and severe 
LV dysfunction. Several important considerations should be integrated in the 
multidisciplinary evaluations of these patients including: the need for MCS at the time of the 
PCI, the types of MCS devices to be used, the timing of the PCI in relation to TAVR, and the 
potential role for concomitant balloon valvuloplasty.
Large registry data have confirmed the safety of PCI (including LM disease) in the setting of 
severe AS, but does not address patients with severe LV dysfunction.3–5,11,12 In a study by 
Goel et al, patients with severe symptomatic AS who had LVEF <30% had a much higher 
post-PCI mortality than patients with preserved LVEF (hazard ratio 2.83, confidence interval 
1.79–4.49, p < 0.001).3 As illustrated in this case, our patient would probably not have 
survived without mechanical circulatory support (Figure 3).
An algorithmic approach to CSD in high-risk patients undergoing complex PCI has been 
outlined in an expert opinion document from the interventional Scientific Council of the 
American College of Cardiology.13 In this algorithm, patients who have severe AS or 
significantly reduced LVED (<30%) should be considered for possible MCS prior to their 
PCI. There are generally four MCS systems commonly used in clinical practice: Intra-aortic 
balloon pump (IABP), the Impella device (Abiomed, Danvers, Massachusetts), 
TandemHeart, and extracorporeal membrane oxygenation (ECMO).13 IABPs are widely 
available, low profile, and easy to insert, and are therefore considered the first-line MCS for 
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many PCIs. Although IABPs decrease after load and increase coronary flow, they provide 
only minimal cardiac output support (0.3–0.5 L/min) and they require a stable or 
synchronous cardiac rhythm. Continuous-flow devices such as the Impella and TandemHeart 
offer a greater level of LV support for high-risk cases. The Impella device is also relatively 
easy to insert, does not increase after load, and improves coronary flow. The TandemHeart 
provides higher cardiac output support compared with the IABP and Impella, but it is not 
widely available and its implantation is more intricate due to the need for transseptal 
puncture, and a larger bore access. Venoarterial extracorporeal membrane oxygenation (VA-
ECMO) provides complete heart and lung support, but can lead to significant increase in 
ventricular after load and often requires additional measures for LV unloading.14 Potential 
complications of all MCS devices are access site bleeding, embolization, limb ischemia, 
infection, stroke, and hemolysis.15 IABPs carry a very small risk of aortic dissection and 
device entrapment.15 Device entanglement and/or fracture, and interactions with the mitral 
valve are uncommon but well described complications of the Impella device.16–20 
TandemHeart insertion carries the risk of adverse events related to transseptal catheterization 
(tamponade, air embolism, iatrogenic atrial septal defect, etc.).21 Lung over-ventilation, 
relative lung ischemia, brain hypoperfusion, and intraventricular thrombus formation are rare 
complications of MCS specific to VA-ECMO.15
The utility of various MCS in patients with severe AS undergoing planned or rescue PCI, 
balloon aortic valvuloplasty (BAV), or TAVR has been demonstrated.9,22–27 However, no 
comparative effectiveness, safety, or cost data between these MCS is available in the 
literature. IABPs have been used on a limited basis in patients with severe AS due to the 
limited cardiac output support they provide.22 The Impella device has been successfully 
used to support high-risk PCI and/or BAV in patients with severe AS (Video S4). Impella 
insertion across very stenotic aortic valves is feasible, but occasionally requires predilatation 
with a 7–10-mm balloon.9,24 While VA-ECMO has been mostly used to salvage AS patients 
due to clinical decompensation or following TAVR, the use of the TandemHeart has been 
mostly limited to elective high risk PCI ± BAV due to the complexity and the required 
expertise for this procedure. A comparison between these MCS systems is illustrated in 
(Figure 4). In this case, the IABP was felt to provide insufficient support for the PCI. ECMO 
was deemed to be less preferable due to the increase in afterload. We elected to use the 
TandemHeart over Impella because it provides higher cardiac output.
BAV has been suggested in patients with severe AS at the time of high-risk PCI.11 However, 
BAV carries substantial risk due to the use of large-bore femoral access, the risk of 
developing significant aortic regurgitation, the risk of embolization and the potential 
compromise of the ostial LM stent during the BAV28,29 (Video S5). The risk of rapid 
ventricular pacing in these high-risk patients can be mitigated by the use of newer 
valvuloplasty balloons such as the Intervalve V8 hourglass shaped balloon (Maquet Medical, 
Wayne, NJ) and the True balloon (Bard, Covington, GA).30 We elected to perform the PCI 
without a concomitant BAV in this case because of the associated risks.
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Baseline coronary and graft angiography. (A) Severe left main stenosis extending into the 
left circumflex (arrow), (B) right coronary artery stenosis (arrow), (C) patent left internal 
mammary bypass graft to left anterior descending and diagonal arteries, (D) occluded 
saphenous vein graft to the obtuse marginal
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Left coronary angiography before and after percutaneous coronary intervention. (A) Left 
main occlusion after guide engagement (arrow), (B) balloon dilatation of the left main/
circumflex, (C) post-balloon dilatation angiogram, (D) post-stenting angiogram
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Peri-procedural arterial pressure monitoring. (A) Low blood pressure at the beginning of the 
procedure, (B) improvement in blood pressure after TandemHeart insertion, (C) near 
complete obliteration of the pulse pressure after left main occlusion, (D) partial recovery of 
the blood and pulse pressures after balloon angioplasty, (E) blood pressure returns to 
baseline post-percutaneous coronary intervention and after TandemHeart removal
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Comparison of mechanical circulatory support systems. AO, aorta; IABP, intra-aortic 
balloon pump; LA, left atrium; LV, left ventricle; LVEDP, left ventricular end-diastolic 
pressure; MAP, mean arterial pressure; PCWP, pulmonary capillary wedge pressure; RA, 
right atrium; VA-ECMO, venoarterial extracorporeal membrane oxygenation. Reprinted 
with Permission, Atkinson et al, JACC Cardiovasc Interv. 2016 9;9(9):871–83
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